Type 1 Diabetes

Our top-read type 1 diabetes articles of 2023 covered increases in rates of pediatric diabetes early in the COVID-19 pandemic, novel therapies for T1D, and links between patient characteristics and T1D outcomes.

Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine, discussed recently published results from the PROTECT trial of teplizumab in patients newly diagnosed with type 1 diabetes (T1D).

A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.

The highest incidence of pediatric type 1 diabetes (T1D) over the past 22 years was seen in Finland, high-income North American regions, and children aged 5 to 14 years.

Researchers concluded there is a clinically important increase in infection risk among patients with T1D in both primary care and hospital settings, and that guidelines must be developed to reflect this risk and encourage earlier treatment.

A study from investigators in Italy sheds further light on the relationship between physical activity and diabetic polyneuropathy risk in patients with type 1 diabetes.

Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.

In a systematic and meta-analysis review of cohort studies that featured nearly 1.7 million individuals, study authors concluded that there is an association between high body mass index (BMI) and an increased risk of incident type 1 diabetes.

High glucose variability in children and young adults with type 1 diabetes (T1D) strongly predicted slowed nerve conduction velocity, a forerunner of diabetic peripheral neuropathy, in a recent study.

Results from the AiDAPT trial show hybrid closed-loop therapy significantly improves maternal glycemic control during pregnancy complicated by T1D.

Phase 3 data presented at ISPAD found that teplizumab-mzwv (Tzield) was better at slowing the progression of type 1 diabetes (T1D) in newly diagnosed children and adolescents.

Results show engaging in unstructured physical activities, even those of low intensity and carried out in the morning and early afternoon, is linked to reduced average glucose levels throughout the day and night.

In the overall population of more than 1.3 million US adults, 37% of patients reported being diagnosed with T1D after 30 years, with men and racial or ethnic minorities diagnosed later compared with women and non-Hispanic White adults.

Updated findings from a phase 1/2 trial of stem-cell derived islet cell therapy for type 1 diabetes (T1D) showed improved glycemic control and a reduction in insulin dependence.

The study aimed to determine the perceived advantages and disadvantages of the smartwatch-integrated, do-it-yourself continuous glucose monitoring (DIY-CGM) device from the perspective of patients with type 1 diabetes (T1D).

Elevated serum endotrophin levels, but not urinary endotrophin levels, predict increased risk of kidney complications and mortality in type 1 diabetes.

Self-care adherence, family support and functioning, and school support also indirectly affected the relationship between sociodemographic and clinical variables and metabolic control, a study found.

The findings suggest that reducing sleep timing variability may help improve metabolic control, but the relationship between glucose levels and sleep variability requires further research.

Type 1 diabetes incidence was 1.14 times higher in the first year and 1.27 times higher in the second year of the COVID-19 pandemic, compared with the 12 months before the pandemic.

The American Diabetes Association (ADA) announced updates to multiple sections of its Standards of Care in Diabetes–2023, as announced at the ADA 83rd Scientific Sessions.

New findings show that VX-880, a stem cell-derived islet cell therapy, can restore endogenous insulin secretion and improve glycemic control in people living with type 1 diabetes (T1D).

Improving access to diabetes technology so that everyone can benefit is a top priority, said David Maahs, MD, PhD, professor of pediatrics at Stanford University and division chief of pediatric endocrinology at Lucile Packard Children’s Hospital.

In a review of adults with type 1 diabetes (T1D), having a body mass index (BMI) <18.5 kg/m2 increased the risk of all-cause mortality by 3.4 times compared with normal BMI.

Individuals with type 1 diabetes (T1D) had brain atrophy patterns equivalent to a brain age about 6 years older than their actual age.

The study also showed that the measurement of HbA1c—which serves as an indicator of clinical assessment—sharply drops in the late teenage years among individuals with type 1 diabetes (T1D).